



California Drug Safety Notification



Notification Name

U. S. FDA Investigating Two Deaths Following Injection of Long-Acting Anti-Psychotic Zyprexa Relprevv

Notification Date	Issue	Recommendation
06/18/13	<i>FDA is investigating two unexplained deaths in patients who received an intramuscular injection of the antipsychotic drug Zyprexa Relprevv (olanzapine pamoate). The patients died 3-4 days after receiving an appropriate dose of the drug, well after the 3-hour post-injection monitoring period required under the Zyprexa Relprevv Risk Evaluation and Mitigation Strategy (REMS). Both patients were found to have very high olanzapine blood levels after death.</i>	FDA is providing this information to health care professionals while it continues its investigation. If therapy with Zyprexa Relprevv is started or continued in patients, health care professionals should follow the REMS requirements and drug label recommendations. Patients and caregivers should talk to their health care professional(s) about any questions or concerns.

FOR ADDITIONAL INFORMATION, PLEASE VISIT:

<http://www.fda.gov/Drugs/DrugSafety/ucm356971.htm>